Search Results
Aug 25, 2026, 08:00 ET CivicaScript® launches 3 low-cost generics to expand its market impact
(everolimus): For full prescribing information and patient information, including important warnings and precautions, potential adverse reactions and drug interactions, please refer to the Package Insert, available
More news about: Civica Rx
Aug 25, 2026, 07:45 ET Vascarta Outlines VAS-101's (Vasceptor®) Potential as a Non-Opioid Advance in Pain Medicine Across Sickle Cell Disease, Osteoarthritis, and Cancer
https://doi.org/10.3389/fpain.2026.17890885. Nugent WH, Prince R, Friedman J, Song BK. Transdermal curcumin gel (VAS-101 drug candidate) improves the microcirculation and tissue oxygenation in a rat model of sickle cell vaso-occlusive episode. J Sickle Cell Dis. 2026;3(1):yoag034.
More news about: Vascarta Inc.
Aug 25, 2026, 07:00 ET Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Evogene Ltd. Shareholders Vote "FOR" the Company's Slate of Highly Qualified Director Nominees
obtained.About Evogene:Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN) is a pioneering company in computational chemistry, specializing in the generative design of small molecules for drug development and ag chemical products. At the core of its technology is ChemPass AI™, a proprietary generative AI designed to explore vast chemical
More news about: Evogene
Aug 25, 2026, 06:15 ET Innovent Announces 2026 Interim Results and Business Updates
weight management to enhance public health awareness.Implemented multiple patient assistance programs, benefiting over 200,000 patients with drug donations valued at over RMB 4 billion.Received honors including "Healthcare Public Welfare Pioneer" and "China Public Welfare Enterprise".Created
More news about: Innovent Biologics
Aug 25, 2026, 06:14 ET Haisco enters into Exclusive License Agreement with new US venture founded by Population Health Partners and ARCH Venture Partners
Partners ("ARCH"), to grant Sentivera the rights to develop, manufacture, and commercialize its independently developed one pre-clinical innovative drug globally, excluding Greater China. The total deal value reaches over USD 1.5 billion, including an upfront payment and equity consideration
More news about: Haisco Pharmaceutical Group
Aug 25, 2026, 06:00 ET Cambrex High Point Completes FDA, PMDA and TGA Pre-Approval Inspections, Advancing Commercial Manufacturing Capabilities
CambrexCambrex is a leading global contract development and manufacturing organization (CDMO) that provides drug substance development and manufacturing across the entire drug lifecycle, as well as comprehensive analytical services.With over 45 years of experience and a
More news about: Cambrex
Aug 25, 2026, 06:00 ET Cambrex High Point Completes FDA, PMDA and TGA Pre-Approval Inspections, Advancing Commercial Manufacturing Capabilities
CambrexCambrex is a leading global contract development and manufacturing organization (CDMO) that provides drug substance development and manufacturing across the entire drug lifecycle, as well as comprehensive analytical services.With over 45 years of experience and a
More news about: Cambrex
Aug 25, 2026, 06:00 ET Cambrex High Point schließt die Inspektionen im Vorfeld der Zulassung durch die FDA, die PMDA und die TGA ab und baut damit seine Kapazitäten für die kommerzielle Produktion weiter aus
drei Inspektionen vor der Zulassung (Pre-Approval Inspections, PAIs) in seinem Werk in High Point, North Carolina, durch die US-amerikanische Food and Drug Administration (FDA), die japanische Arzneimittel- und Medizinproduktebehörde (PMDA) sowie die australische Therapeutic Goods Administration (TGA) bekannt.
More news about: Cambrex
Aug 25, 2026, 02:56 ET Senhwa Completes Enrollment in Phase 1b CX-5461 Expansion Trial; CSR Expected in Q1 2027
treated with PARP inhibitors. They also provide a clinical rationale for evaluating CX-5461 in combination with PARP inhibitors, immunotherapies, antibody-drug conjugates, and other precision oncology agents.As the HRD treatment landscape moves beyond PARP inhibitor monotherapy toward resistance-overcoming
More news about: Senhwa Biosciences, Inc.
Aug 24, 2026, 20:30 ET Antengene Receives Clinical Trial Approval in Australia for Phase I ATTRACT Study of ATG-201 (CD19 x CD3 TCE) in B Cell-related Autoimmune Diseases
CD3 (ATG-107 for acute myeloid leukemia).To date, Antengene has obtained 34 investigational new drug (IND) approvals in the U.S. and Asia, and obtained new drug application (NDA) approvals in 10 Asia Pacific markets. Its lead commercial asset, XPOVIO® (selinexor), is
More news about: Antengene Corporation Limited
Aug 24, 2026, 19:30 ET Astellas Doses First Patient in Phase 3 Study of ASP2138 in CLDN18.2-postive and HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
2025;36(Suppl 2):S1120. doi:10.1016/j.annonc.2025.08.2755.U.S. National Cancer Institute. Anti-CLDN18.2/anti-CD3 bispecific antibody ASP2138. NCI Drug Dictionary. [Online] Available at:
More news about: Astellas Pharma Inc.
Aug 24, 2026, 19:12 ET FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients
HOUSE, Pa., Aug. 24, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced the U.S. Food and Drug Administration (FDA) approval of IMAAVY® (nipocalimab-aahu) for the treatment of warm autoimmune hemolytic anemia (wAIHA) – a rare, life-threatening
More news about: Johnson & Johnson
Aug 24, 2026, 16:32 ET Capricor Therapeutics, Inc. Investor Alert - Robbins LLP Reminds CAPR Investors with Significant Losses of the Opportunity to Lead the Class Action Lawsuit Against the Company
complications associated with DMD.According to the complaint, Capricor submitted a Biologics License Application ("BLA") to the U.S. Food and Drug Administration ("FDA") for Deramiocel in late 2024. In July 2025, the FDA issued a Complete Response Letter stating that the BLA did not meet the statutory
More news about: Robbins LLP
Aug 24, 2026, 13:53 ET Nixodine-S™ Study Signals a Potential Breakthrough Beyond Nicotine
products or health-care treatments. Human clinical trials have not been completed. Product claims have not been evaluated or approved by the U.S. Food and Drug Administration or another governmental regulatory body. This release describes non-clinical, formulation-specific findings and does not claim that Nixodine-S
More news about: Bonguard Naturals
Aug 24, 2026, 12:35 ET UT Health San Antonio names NIH expert inaugural director of stem cell transplant and cellular therapy program
studies. His research helped move forward treatments for blood cancers and serious blood disorders, including work that contributed to the U.S. Food and Drug Administration approval of a stem cell-based therapy for patients with blood cancers.Advancing cancer care in South TexasThe Mary
More news about: The University of Texas Health Science Center at San Antonio
Aug 24, 2026, 12:32 ET CAPR Stock Alert: Capricor Therapeutics, Inc. (CAPR) Reports Q2 Earnings Amid Ongoing Securities Class Action Lawsuit - Hagens Berman
allegedly failed to disclose that they adopted changes to the pre-specified statistical analysis plan (SAP) without agreement from the U.S. Food and Drug Administration (FDA) prior to resubmitting its Biologics License Application (BLA).The HOPE-3 Trial Breakthrough and
More news about: Hagens Berman Sobol Shapiro LLP
Aug 24, 2026, 12:21 ET AARD Investor Notice: Hagens Berman Alerts Investors in Aardvark Therapeutics (NASDAQ: AARD) to Filing of Securities Class Action
stock price plummeted over 56%. May 14, 2026: Aardvark announced that the U.S. Food and Drug Administration (FDA) placed a full clinical hold on its investigational new drug application (IND) for ARD-101, halting all ongoing studies under the IND, including the Phase 3 HERO trial and
More news about: Hagens Berman Sobol Shapiro LLP
Aug 24, 2026, 11:00 ET BRC Therapeutics Appoints Biopharma Veteran Chandra Ramanathan as Executive Vice President of Commercialization and Strategy
Seasoned Executive Brings Track Record of Drug Launches, External Innovation, and Portfolio Growth at Bristol Myers Squibb, Wyeth, Bayer, and Danaher to BRC's Next Phase of GrowthMONTEREY, Calif., Aug.
More news about: BRC Therapeutics
Aug 24, 2026, 10:46 ET Vascular Innovation Takes Center Stage at The VEINS and VIVA 2026
Percutaneous Intervention vs Surgery for the Treatment of CFA LesionsThomas Zeller, MDReal-World 6-Month Outcomes of the Esprit BTK Drug-Eluting Resorbable Scaffold in CLTI: Results From the Post-Approval StudyBrian DeRubertis, MDClinical Outcomes of the MOTIV Sirolimus-Eluting
More news about: The VIVA Foundation
Aug 24, 2026, 10:31 ET Liver Cirrhosis Market to Expand Significantly Through 2036, Driven by Emerging Therapies and Increasing Disease Burden | DelveInsight
administration, EFX has demonstrated consistent and robust clinical activity, supporting its potential to become a best-in-class therapy if approved. The drug is currently being assessed in the Phase IIb SYMMETRY trial involving patients with biopsy-confirmed MASH and compensated F4 cirrhosis. Clinical findings
More news about: DelveInsight Business Research, LLP
Aug 24, 2026, 09:47 ET CLASS ACTION NOTICE: Berger Montague Advises Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to Inquire About a Securities Fraud Class Action
suffering from Duchenne's muscular dystrophy.As the lawsuit alleges, on July 27, 2026, before the market opened, the U.S. Food and Drug Administration ("FDA") released briefing documents ahead of its July 29 advisory committee ("AdCom") meeting for the biologics license application ("BLA")
More news about: Berger Montague
Aug 24, 2026, 09:16 ET Dove Men+Care and Basketball Champion Karl-Anthony Towns Team Up to Help Men Find Their Vibe with Plant-Powered Body Wash Campaign
portfolio that includes bars, body washes, face care, antiperspirant/deodorants, hair care, and hand/body lotions, which are available nationwide in food, drug, and mass outlet stores. Learn more at DoveMenCare.com.About Unilever Unilever is one of the world's leading suppliers of Beauty
More news about: Dove Men+Care
Aug 24, 2026, 09:03 ET WILD ABOUT SPROUTS RESPONDS TO MULTISTATE SPROUT OUTBREAK WITH CALL FOR GREATER SAFETY, TRANSPARENCY AND ACCOUNTABILITY
The U.S. Food and Drug Administration has advised consumers, retailers, and foodservice operators not to eat, sell, or serve the products identified in its advisory while
More news about: Rä Foods LLC
Aug 24, 2026, 09:02 ET Amplifica Appoints Hans Hofland, Ph.D., as Chief Development Officer and William Humphries to Board of Directors
Appointments add deep dermatology drug development and commercialization expertise as Amplifica advances its hair-growth pipelineSAN DIEGO, Aug. 24, 2026 /PRNewswire/ -- Amplifica Holdings Group,
More news about: Amplifica Holdings Group, Inc.
Aug 24, 2026, 08:43 ET Leqembi Iqlik® for initiation treatment launched in the US
maintenance treatment of early Alzheimer's disease. In November 2025, a new drug application for subcutaneous formulation of Leqembi was submitted in Japan. In December 2025, Leqembi was included in the "Commercial Insurance Innovative Drug List", recently introduced by the National Healthcare Security Administration
More news about: BioArctic